These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 11223696)

  • 1. Do we know everything about alpha-blockade in the management of lower urinary tract symptoms?
    Puppo P
    Eur Urol; 2001 Jan; 39 Suppl 2():38-41. PubMed ID: 11223696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostatic and extraprostatic alpha-adrenoceptors--contributions to the lower urinary tract symptoms in benign prostatic hyperplasia.
    Andersson KE
    Scand J Urol Nephrol Suppl; 1996; 179():105-11. PubMed ID: 8908675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential mechanisms of action of superselective alpha(1)-adrenoceptor antagonists.
    Price D
    Eur Urol; 2001; 40 Suppl 4():5-11. PubMed ID: 11786674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Benign hypertrophy of the prostate: which treatment, for whom?].
    Schulman C
    Rev Med Brux; 1999 Sep; 20(4):A212-8. PubMed ID: 10523895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Uroselectivity of alpha-1 antagonism in the treatment of benign prostatic hypertrophy: on the pharmacologic concept of the clinical approach].
    Jolliet P; Bourin M
    Therapie; 1998; 53(1):61-6. PubMed ID: 9773101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamsulosin in the treatment of LUTS/BPH: an Italian multicentre trial.
    Muzzonigro G
    Arch Ital Urol Androl; 2005 Mar; 77(1):13-7. PubMed ID: 15906783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: alpha-blockers in the treatment of male voiding dysfunction - how do they work and why do they differ in tolerability?
    Michel MC
    J Pharmacol Sci; 2010; 112(2):151-7. PubMed ID: 20134112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Our experience with the treatment of benign prostatic hyperplasia (BPH) with tamsulosin.
    Cervenakov I; Fillo J
    Bratisl Lek Listy; 2001; 102(3):138-41. PubMed ID: 11433602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance?
    Barendrecht MM; Abrams P; Schumacher H; de la Rosette JJ; Michel MC
    Neurourol Urodyn; 2008; 27(3):226-30. PubMed ID: 17638312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Miyakita H; Yokoyama E; Onodera Y; Utsunomiya T; Tokunaga M; Tojo T; Fujii N; Yanada S
    Int J Urol; 2010 Oct; 17(10):869-75. PubMed ID: 20735791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists.
    Andersson KE
    World J Urol; 2002 Apr; 19(6):390-6. PubMed ID: 12022707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial comment to short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Gravas S
    Int J Urol; 2010 Oct; 17(10):875. PubMed ID: 20887633
    [No Abstract]   [Full Text] [Related]  

  • 14. Nocturnal polyuria in patients with lower urinary tract symptoms and response to alpha-blocker therapy.
    Koseoglu H; Aslan G; Ozdemir I; Esen A
    Urology; 2006 Jun; 67(6):1188-92. PubMed ID: 16750254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
    Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E;
    Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New clinical evidence of silodosin, an α(1A) selective adrenoceptor antagonist, in the treatment for lower urinary tract symptoms.
    Yoshida M; Kudoh J; Homma Y; Kawabe K
    Int J Urol; 2012 Apr; 19(4):306-16. PubMed ID: 22251148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Storage and voiding symptoms: pathophysiologic aspects.
    Andersson KE
    Urology; 2003 Nov; 62(5 Suppl 2):3-10. PubMed ID: 14662401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Gallegos PJ; Frazee LA
    Pharmacotherapy; 2008 Mar; 28(3):356-65. PubMed ID: 18294115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Use of alpha1-adrenergic blockaders in treating voiding disorders after transurethral resection of the prostate].
    Martov AG; Gushchin BL; Oshchepkov VN; Ergakov DV
    Urologiia; 2002; (5 Suppl):23-37. PubMed ID: 12518670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.